<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086511</url>
  </required_header>
  <id_info>
    <org_study_id>MBB18TA18444</org_study_id>
    <nct_id>NCT04086511</nct_id>
  </id_info>
  <brief_title>PANDA: PKU Amino Acid Evaluation</brief_title>
  <acronym>PANDA</acronym>
  <official_title>PANDA: A Cross-sectional Study to Measure Blood Amino Acid Levels in PKU Children on a Protein Substitute</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutricia Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutricia Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenylketonuria (PKU) is a rare inherited metabolic disorder, where subjects are born with a&#xD;
      genetic deficiency in the phenylalanine hydroxylase enzyme (PAH), which leaves them unable to&#xD;
      convert Phenylalanine (Phe) into Tyrosine (Tyr). PKU patients have specific dietary needs and&#xD;
      must follow a restrictive diet in the aim of preventing toxic levels of the amino acid&#xD;
      phenylalanine (Phe) accumulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The exploratory study's main objective is to measure blood amino acid levels and to gain&#xD;
      quantitative insights in children with PKU on a protein substitute with respect to evaluation&#xD;
      of nutritional intake.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amino acid levels in blood</measure>
    <time_frame>day 1</time_frame>
    <description>Measuring amino acid levels in blood [μmol/L]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nutrient Intake</measure>
    <time_frame>day 1 - day 3</time_frame>
    <description>Measured by three-day diet diary. Nutrients in [mg/day]</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Phenylketonuria (PKU)</condition>
  <arm_group>
    <arm_group_label>Children with PKU</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Age- and sex-matched non-PKU comparison subjects</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with PKU and age- and sex-matched non-PKU comparison subjects. Sites that&#xD;
        participate: Belgium and Poland&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Both PKU and Non-PKU comparison subjects:&#xD;
&#xD;
          1. Age ≥ 2 and ≤ 12 years&#xD;
&#xD;
          2. Willing and able to provide informed consent by parents or legal representatives (and&#xD;
             assent if required by local law/regulations)&#xD;
&#xD;
          3. One subject per family&#xD;
&#xD;
             PKU subjects specific inclusion criteria:&#xD;
&#xD;
          4. PKU subjects identified by newborn screening and started low Phe diet before 1 month&#xD;
             age&#xD;
&#xD;
          5. Usage of at least two Phe-free protein substitutes on a daily basis for at least 26&#xD;
             consecutive weeks up to Visit 1&#xD;
&#xD;
          6. Average Phe-level ≤360 µmol/L based on at least two blood Phe values from the past 12&#xD;
             months up to Visit 1&#xD;
&#xD;
             Non-PKU comparison subjects specific inclusion criteria:&#xD;
&#xD;
          7. Same age (±3 years) and sex as an included PKU subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Both PKU and Non-PKU comparison subjects:&#xD;
&#xD;
          1. Current psychiatric disorders&#xD;
&#xD;
          2. Severe hepatic, thyroid or renal dysfunction&#xD;
&#xD;
          3. Acute illnesses like fever, flu, diarrhea, or vomiting (subjects should be symptom&#xD;
             free for a week prior to V1)&#xD;
&#xD;
          4. Serious conditions (e.g. cancer, hydrocephalus, fatal heart disease)&#xD;
&#xD;
          5. Participation in any other clinical intervention studies involving test products&#xD;
             concomitantly or within six weeks prior to entry into the study&#xD;
&#xD;
             PKU specific exclusion criteria:&#xD;
&#xD;
          6. Use of BH4, or drugs that may interfere with main outcomes&#xD;
&#xD;
             Non-PKU comparison subjects specific exclusion criteria:&#xD;
&#xD;
          7. PKU diagnosis or any other diagnosed disorder of amino or organic acid metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dr. P. Verloo</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Gent, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nutricia Research</last_name>
    <phone>0031 30 295 000</phone>
    <email>register.clinicalresearchnutricia@danone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. P. Verloo</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

